
Ontada Names Christine Davis Its New President

In this role, Davis will focus on growing the business and fostering innovation, all to improve the lives of patients and win the fight against cancer. With more than 25 years of experience in the life sciences industry, Davis possesses an impressive background in oncology research and real-world data.
“Christine has a strong track record of driving significant business growth and transformation,” said Kirk Kaminsky, president of Pharmaceutical Solutions and Services at McKesson. “We’re confident she will lead the way in harnessing Ontada’s real-world data and evidence, along with McKesson’s unmatched portfolio of oncology services, to improve health outcomes for patients living with cancer.”
In her newly appointed position, Davis will advance Ontada’s real-world data and evidence services that are helping to accelerate drug development and commercialization, educate providers on new treatments, and advance precise, evidence-driven patient care. Additionally, she aims to enhance
Previously, Davis served as the Oracle Life Sciences’ Global Head of Commercial Research & Consulting for Cerner Enviza. She worked her way into life sciences leadership while at Kantar Health, a data analytics and research company focused on oncology and rare diseases later acquired by Cerner.
At Kantar, Davis led the research business and directed U.S. primary research and analytics into opportunities for growth, differentiation, and innovation on behalf of the world’s top pharmaceutical companies. She later served as global head of oncology and specialty therapeutics where she led the company’s oncology data and products business. Davis holds a master’s from Northeastern University and a BS in Nutrition and Biochemistry from Syracuse University.
“Playing an integral part in improving the lives of cancer patients is something to be proud of, and it drives me to go to work with such purpose. I am glad to be joining Ontada’s amazing team, whose members have the same passion to drive transformation and innovation in an ever-evolving field,” said Davis. “With the support of McKesson and the strength of Ontada, I see so much opportunity to bring real and powerful impact to patient lives.”
About Ontada®
About McKesson Oncology and Specialty Solutions
It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At
- McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through the joint venture between US Oncology Research and
Sarah Cannon Research Institute . The US Oncology Network andMcKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.Ontada ®,a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE) and provides clinical education and provider technology to inform and improve cancer care.- As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
- And through
CoverMyMeds ,Biologics by McKesson , andGPO services , our work continues to help patients access, afford, and adhere to their medicines.
SOURCE: Ontada
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.